Trials in set up

These are brief descriptions of trials currently in set up.  Information will be updated as soon as details are finalised, centres are known and the trials are starting.

The ABC-12 study is due to open soon:
ABC-12: Exploring the microbiome in patients (pts) with advanced biliary tract cancer (BTC) in a first-line study of durvalumab in combination with cisplatin/gemcitabine (cis/gem). All patients will receive durvalumab and CisGem (as in the TOPA-1 study) and this study is evaluating the microbiome of patients undergoing treatment. A good bridge enabling access before NICE have reviewed durvalumab. Chief Investigator: Mairéad McNamara at The Christie